Cell Biotech Co Ltd

Cell Biotech Co Ltd maintains a strong liquidity position with a current ratio of 21.34, indicating significant short-term asset coverage over liabilities. Despite a negative cash and equivalents balance of -KRW 250, the company's free cash flow of KRW 7.45 billion and operating cash flow of KRW 11.11 billion suggest robust cash generation. The price-to-book ratio of 0.86 implies the market values the company below its book value, while the price-to-earnings ratio of 11.12 is relatively modest. Profitability metrics show a return on equity of 7.69% and return on assets of 7.41%, both exceeding the typical thresholds for pharmaceutical firms. The company's operating margin of 14.9% (calculated from operating income of KRW 7.92 billion on revenue of KRW 53.13 billion) is strong, though it should be benchmarked against industry medians for a complete assessment. The company's revenue is concentrated in a single business segment focused on pharmaceuticals and supplements, with no disclosed geographic diversification beyond South Korea. This lack of segment or geographic diversification increases exposure to domestic regulatory and economic shifts. Outlook data indicates a projected revenue increase of 8.2% in the current fiscal year and 5.1% in the next, driven by new product launches and expanded distribution channels. The company's capital expenditure of -KRW 3.21 billion in the latest period suggests a focus on cost optimization rather than expansion. Risk factors include a negative net cash position and the absence of long-term debt, which may limit flexibility in capital allocation. The dilution risk is assessed as low, with no near-term pressure from share issuance or convertible instruments. No material dilution adjustments were applied in the valuation process. Recent filings and transcripts highlight the company's focus on R&D for new probiotic formulations and its strategy to expand into adjacent health supplement markets.